Guangzhou

Running trials

• Active, not recruiting

  Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

  NCT05463601· Phase 2· Source

• Active, not recruiting

  A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

  NCT02489318· Phase 3· Source

• Active, not recruiting

  An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

  NCT02531516· Phase 3· Source

• Active, not recruiting

  A Long-term Extension Study of PCI-32765 (Ibrutinib)

  NCT01804686· Phase 3· Source

• Recruiting

  Product Surveillance Registry

  NCT01524276· Source

• Recruiting

  Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

  NCT00271180· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting
• Heart failure1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

  NCT01776840· Phase 3· Source

• Completed

  AI Multitask Model for HCC Treatment

  NCT07157085· Source